tranexamic acid has been researched along with Conus Medullaris Syndrome in 2 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty consecutive patients with cervical compressive myelopathy were prospectively randomized into groups that received 15 mg/kg body weight of TXA or placebo intravenously before the skin incision was made." | 2.76 | Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study. ( Misawa, H; Ohta, H; Shimogata, M; Tsutsumimoto, T; Yoda, I; Yui, M, 2011) |
| "Patients suffered from acute spinal cord compression caused by spinal tumor manifestation (n = 5), empyema (n = 4), degenerative spinal stenosis (n = 1), hematoma (n = 1), and vertebral body fracture/dislocation (n = 2)." | 1.51 | Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants. ( Beynon, C; Gumbinger, C; Olivares, A; Unterberg, AW; Younsi, A; Zweckberger, K, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beynon, C | 1 |
| Olivares, A | 1 |
| Gumbinger, C | 1 |
| Younsi, A | 1 |
| Zweckberger, K | 1 |
| Unterberg, AW | 1 |
| Tsutsumimoto, T | 1 |
| Shimogata, M | 1 |
| Ohta, H | 1 |
| Yui, M | 1 |
| Yoda, I | 1 |
| Misawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
1 trial available for tranexamic acid and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
Tranexamic acid reduces perioperative blood loss in cervical laminoplasty: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cervical Vertebrae; F | 2011 |
1 other study available for tranexamic acid and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Management of Spinal Emergencies in Patients on Direct Oral Anticoagulants.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Blood Coagulation Factors; Bl | 2019 |